Gold prices slip slightly after recent gains; U.S. data eyed
Ryan Fukushima, the Chief Operating Officer of Tempus AI , Inc. (NASDAQ:TEM), recently executed a series of stock sales totaling approximately $1.02 million. The transactions, which took place on March 4, 2025, involved the sale of Class A Common Stock at prices ranging from $47.48 to $53.56 per share. The stock, currently trading at $48.86, has experienced a -4.05% decline over the past week, with the company carrying a market capitalization of $9.1 billion. Following these transactions, Fukushima retains 924,460 shares of Tempus AI in direct ownership. The sales were conducted under a pre-established Rule 10b5-1 trading plan, which was adopted in June 2024. According to InvestingPro analysis, TEM is currently trading above its Fair Value, with additional insights available in the comprehensive Pro Research Report covering insider trading patterns and valuation metrics among 1,400+ top stocks.
In other recent news, Tempus AI Inc reported a 35.8% increase in fourth-quarter revenue for 2024, reaching $700 million. Despite this growth, the company’s earnings per share (EPS) were negative at -0.18. Tempus AI has raised its 2025 revenue guidance to approximately $1.24 billion, including contributions from Ambry Genetics, which it recently acquired. JPMorgan has downgraded Tempus AI from Overweight to Neutral, although it raised the price target to $55, citing a fully valued stock. Stifel analysts maintained a Hold rating on the stock with a $65 price target, noting that its valuation appears fair compared to industry peers.
Tempus AI’s core business is expected to grow by over 30% year-over-year, driven by pricing benefits in the Genomics sector and momentum in Data & Services. The company also launched the Olivia AI personal health app, further expanding its product offerings. Additionally, Tempus AI’s total remaining contract value stands at $940 million, indicating strong future revenue potential. The company anticipates an adjusted EBITDA of $5 million for the current year, revising its previous expectation of achieving positive adjusted EBITDA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.